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S22 Journal of Thoracic Oncology Vol. 11 No. 2Ssynthesized using an independent method, and
sequenced by Sanger. The results conﬁrmed the
presence of an RNA transcript spanning exon 19 of
MPRIP and exon 12 of RET. Furthermore, FISH was
performed with the RET (10q11.2) break-apart probe,
and conﬁrmed the rearrangement involving the RET
region of chromosome 10.
Conclusions: These results show the ArcherTM Fusion-
PlexTM Lung Thyroid Panel can accurately detect gene
fusions with both known and unknown partner and
driver genes. Further investigation is needed to better
understand the clinical signiﬁcance and prevalence of
the novel MPRIP and RET fusion.
The transcription factor Slug induces
diverse malignant phenotypes in
models of established lung cancer
and pulmonary premalignancyBrandon S. Grimes, Tonya C. Walser, Rui Li,
Zhe Jing, Linh Tran, Steven M. Dubinett David
Geffen School of Medicine at UCLA, Los Angeles, CA
Inﬂammation often characterizes the pulmonary tumor
microenvironment, as does overexpression of the tran-
scriptional repressors of E-cadherin (e.g., Snail and Slug).
While chronic inﬂammation is now associated with
increased lung cancer incidence, Snail and Slug are still
best known for their induction of epithelial-mesen-
chymal transition (EMT) and their contribution to the
progression of established lung cancer. Our bioinfor-
matics analysis of lung TCGA data suggests that Slug is
among the most impactful of all the transcriptional re-
pressors on patient survival. Therefore, we are now
exploring the scope of malignant phenotypes and
mechanisms induced by Slug expression in a non-small
cell lung cancer (NSCLC) model. We discovered that
NSCLC cells exposed to the prototypical inﬂammatory
mediator IL-1B respond with downregulation of epithe-
lial markers (E-cadherin and cytokeratin 18) and upre-
gulation of mesenchymal markers (N-cadherin and
vimentin), with the repression of E-cadherin by IL-1B
being Slug-dependent. NSCLC cells exposed to IL-1B also
demonstrate altered cellular morphology, diminished
capacity to form clusters in a 3-dimensional (3D)
spheroid model, and increased motility. Using chemical
inhibitors of the JNK, MEK/ERK, p38 MAPK, and NF-lB
pathways, we determined that JNK and MEK/ERK
mediate IL-1B induction of EMT in lung cancer cells.
Furthermore, siRNA-mediated knockdown of the Fra-1
component of the AP-1 transcription factor abolished the
impact of IL-1B on Slug and E-cadherin in this model,demonstrating a mechanistic link between inﬂammation
and Slug-dependent progression of established lung
cancer. Because we have identiﬁed a critical role for
Snail in lung cancer initiation, we next investigated the
contribution of Slug to early lung cancer development.
Using human bronchial epithelial cells (HBECs) engi-
neered to express Slug to model pulmonary pre-
malignancy, we observed a diverse array of potentially
malignant phenotypes, including EMT, increased pro-
duction of the pro-angiogenic chemokine CXCL8,
enhanced invasion in a 3D air-liquid interface model, and
anchorage-independent growth in vitro. Furthermore,
we determined that the Slug-driven transformation
observed in vitro was not contingent upon an altered
proliferation rate, but was more likely related to Slug-
driven disruption of stem cell signaling programs. Taken
together, our data suggest that Slug may be important
in the setting of lung carcinogenesis and that its impact
on carcinogenesis extends beyond its repression of
E-cadherin. Our data also suggest that Slug may play an
important role in the initiation and progression of early
stage NSCLC.
Structural analysis identiﬁes an orally
active PCNA inhibitor that inhibits the
growth of small cell lung cancer cells
without causing signiﬁcant toxicity to
nonmalignant cellsLong Gu, Robert J. Hickey, Karen L. Reckamp,
Linda H. Malkas Beckman Research Institute of
City of Hope, Duarte, CA
Playing a central role in regulating DNA synthesis and
repair, proliferating cell nuclear antigen (PCNA) is
indispensable to cancer cell growth and survival. It,
therefore, represents a potential molecular target to
develop broad-spectrum anti-cancer agents. We discov-
ered a cancer-associated isoform of PCNA (caPCNA),
which is ubiquitously and highly expressed in a broad
range of cancer cells and tumor tissues. In contrast, this
PCNA isoform is not signiﬁcantly expressed in non-
malignant cells. The secondarily modiﬁed region dis-
tinguishing caPCNA from normal PCNA expressed in
non-malignant cells lies between L126 and Y133 within
the interconnector domain of PCNA known to be a major
binding site for many of PCNA’s interacting proteins. A
cell permeable peptide containing the L126-Y133
sequence blocks PCNA interaction, interferes with
DNA replication and homologous combination mediated
DNA repair, and induces apoptosis in cancer cells. In
contrast, this peptide causes no signiﬁcant toxicity to
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that the L126-Y133 region forms part of a pocket suit-
able for binding by a small molecule. We designed and
tested a series of small molecules that target this binding
pocket and identiﬁed AOH1160, a potent PCNA inhibitor,
which kills small cell lung cancer (SCLC) cells at high
nanomolar concentrations, but causes no signiﬁcant
toxicity to a broad range of non-malignant cells up to a
concentration of 10 mM. AOH1160 is orally available to
animals and inhibits tumor growth without causing any
observable side-effects, including weight loss, in mice.
These studies demonstrated the feasibility of inhibiting
the growth of SCLC cells by targeting a speciﬁc region of
PCNA without causing unacceptable toxicity to normal
tissues. Further development of AOH1160 may lead to a
novel anti-cancer therapy.Translational application of microRNA
proﬁling for early detection of lung
cancer: A comparison of sputum and
bloodJennifer E. Gyoba, Rene Razzak,
Sunita Ghosh, Linghong Guo, Wilson Roa,
Eric L.R. Bedard University of Alberta, Edmonton, AB,
Canada
Background: Lung cancer has the highest mortality
rates of all the cancers in Canada with a 5 year survival
rate of less than 15%. Asymptomatic in its early stages,
methods to screen high risk individuals are in dire need
to allow earlier diagnosis and curative intent treatment.
MicroRNAs (miRNAs) are small, non-coding strands of
RNA that are shown to lead to carcinogenesis when
dysregulated. They are promising candidates for bio-
markers as they are stable, detectable in small quantities
and are expressed in a tissue speciﬁc manner. Through
the use of a miRNA panel developed by our group that
demonstrated good sensitivity and speciﬁcity using
sputum as a medium to measure miRNA., we aimed to
compare the efﬁcacy of measuring miRNA in sputum and
blood to develop a miRNA proﬁle for non-small cell lung
cancer (NSCLC).
Objective: To examine miRNA proﬁles of NSCLC cases
versus healthy controls to compare the efﬁcacy of
sputum and blood for potential screening purposes us-
ing microarray analysis.
Methods: A case control study of stage I/II cancers,
matched with controls having similar smoking history,
age, and gender, was performed. Participants were
recruited at the Royal Alexandra Hospital in Edmon-
ton, Alberta, Canada. Both sputum and blood arecollected and analyzed via Qiagen miRNA kits. 10
cases and 10 controls miRNA samples were submitted
for microarray analysis. miRNAs were labelled, hy-
bridized, and quantiﬁed using single-color experi-
mental design. Speciﬁc miRNAs from past literature
were then compared in cases and controls using Mann
Whitney U test.
Results: Sputum does not have consistent levels of
miRNA present when compared to blood, and principle
component analysis (PCA) plots show more random
patterns in sputum when compared to blood. By using
heat maps and hierarchical clustering, no apparent
clusters are seen when compared cases and controls in
both sputum and blood. A type II error could be
responsible for this ﬁnding due to the small sample size.
In an independent analysis looking at speciﬁc miRNAs
seen to be dysregulated in past literature, miR-147a is
signiﬁcantly different in sputum, and miR-126-5p is
signiﬁcantly different in blood.
Conclusions: Microarray analysis shows that sputum
is less consistent when measuring miRNAs compared
to blood overall. These ﬁndings have already been
applied to the next phase of our research which will
examine miRNA levels in high risk individuals as a
means of establishing it as a robust screening test for
lung cancer.Targeting immunosuppressive
mechanisms in KRAS mutant
lung cancerLauren Smith Havel, Dingcheng Gao,
Jennifer S. Daniel, Nasser K. Altorki,
Vivek Mittal Neuberger Berman Foundation Lung Cancer
Center, Weill Cornell Medical College, New York, NY
Clinical trials with single agent immune checkpoint in-
hibitors, mainly the anti-PD-1 antibody, have achieved
noteworthy beneﬁt with an objective response rate in
17% of non-small cell lung cancer (NSCLC) patients.
However, minimal or no response in a large proportion
of patients suggest that additional immune suppression
pathways need to be identiﬁed in the tumor microenvi-
ronment to deﬁne combination immune therapies for
future therapeutic intervention. We have focused our
studies on the KRAS mutant subset, as it accounts for
>30% of NSCLC patients with high mortality rates due
to a conspicuous lack of effective FDA approved targeted
therapies.
To enable selection of appropriate immunother-
apies, we have performed comprehensive analysis of
immune microenvironments in a mouse model of
